Hong Kong Software Stock News

SEHK:1898
SEHK:1898Oil and Gas

How Investors Are Reacting To China Coal Energy (SEHK:1898) August Production Update

China Coal Energy reported August 2026 data showing commercial coal production and self produced coal sales below the prior year, while several chemical products such as polyethylene and polypropylene recorded higher volumes. The mix of softer coal volumes alongside relatively resilient chemicals output signals shifting demand and capacity use within China Coal Energy's coal and coal chemicals portfolio. In the following sections we examine how China Coal Energy's investment narrative is...
SEHK:9926
SEHK:9926Biotechs

Is Akeso (SEHK:9926) Undervalued On New Ivonescimab Survival Data?

Akeso (SEHK:9926) is back in focus after presenting new overall survival data from its Phase III HARMONi-2 trial of ivonescimab versus pembrolizumab in first-line PD-L1-positive non-small cell lung cancer at WCLC 2026. Akeso’s HK$95.25 share price has drifted lower over the year to date with a decline of 15.93%, yet a 13.53% 3 month share price return and a 3 year total shareholder return of 151.98% suggest long term holders have still seen strong gains as sentiment oscillates around each new...
SEHK:384
SEHK:384Gas Utilities

How Investors Are Reacting To China Gas Holdings (SEHK:384) Long Term LNG Supply Deal

Venture Global and China Gas Holdings previously announced a 20-year Sales and Purchase Agreement for 0.5 million tonnes per annum of U.S. LNG from 2030, lifting China Gas's contracted LNG offtake with Venture Global to 2.5 million tonnes per year. The additional volumes deepen China Gas Holdings' access to long-term U.S. LNG and support its goal of building an international energy trading platform that links overseas supply with growing demand. We will now examine how China Gas Holdings'...
SEHK:28
SEHK:28Real Estate

Asian Market Gems: Promising Penny Stocks For September 2026

As the Asian markets navigate a landscape marked by geopolitical tensions and fluctuating oil prices, investors are keenly observing opportunities that may arise amidst these challenges. Penny stocks, despite their somewhat outdated moniker, continue to attract attention for their potential to offer growth opportunities in smaller or emerging companies. This article will explore three such stocks that not only demonstrate financial resilience but also present intriguing possibilities for...
SEHK:991
SEHK:991Renewable Energy

Why Datang International Power Generation (SEHK:991) Is Getting Attention Today

Datang International Power Generation (SEHK:991) has drawn fresh attention after a recent price move left the share price at HK$2.645. Investors are weighing this level against the group’s substantial power generation footprint across China. Recent trading tells a mixed story. The 1 day share price return declined 1.67% and the 7 day share price return slipped 2.76%. However, Datang International Power Generation still shows a 30 day share price return of 8.62% and a year to date share price...
SEHK:863
SEHK:863Capital Markets

3 Stocks Exposed To Stablecoin Rules And Cross Border Payment Growth

Markets are being rewired in real time as fresh transparency rules, tighter investor protections and shifting geopolitics reshape how capital moves across borders. That kind of structural change can reward firms that adapt early and expose laggards that do not. This article unpacks that story and profiles 3 stocks from a Global Exchanges & Market Infrastructure Providers screener that appear particularly exposed to the latest round of regulatory and geopolitical crosswinds. The stocks...
SEHK:3306
SEHK:3306Luxury

Full Year Earnings Change The Bull Case For JNBY Design Stock (SEHK:3306)?

JNBY Design reported full year results to June 30, 2026, with sales of CNY 6,046.26 million and net income of CNY 997.45 million, alongside higher basic and diluted earnings per share from continuing operations compared with the prior year. The company delivered this higher full year profit while also managing board succession, as a key independent director prepares to retire and committee leadership shifts to another independent member. This article examines how JNBY Design's higher full...
SEHK:1801
SEHK:1801Biotechs

Is Innovent Biologics (SEHK:1801) Fairly Valued On LP 003 China BLA Progress?

The National Medical Products Administration has accepted LongBio Pharma’s Biologics License Application for LP-003, supported by Innovent Biologics (SEHK:1801) subsidiary Altruist Biologics, marking China’s first anti-IgE BLA for seasonal allergic rhinitis. For investors tracking Innovent Biologics, the latest regulatory milestone lands after a mixed stretch in the market, with the share price slipping 1.9% over the last session and 5.2% across the week, yet recording a 26.9% 90 day share...
SEHK:1310
SEHK:1310Telecom

How Investors Are Reacting To HKBN (SEHK:1310) Board Chair Change

HKBN reported that on 11 September 2026, Ling Hao stepped down as executive director, chairman and nomination committee chair, with China Mobile Hong Kong chief executive Shi Xiaoping taking over all three roles. The move brings HKBN a leader with over 25 years of telecom execution experience across network build out, operations, compliance and enterprise-facing services. This could influence how the business prioritises broadband, ICT and partnership decisions. It remains to be seen how...
SEHK:152
SEHK:152Infrastructure

Is Shenzhen International Holdings (SEHK:152) Undervalued After Its RMB 1b Note Issuance?

Shenzhen International Holdings (SEHK:152) has completed a fresh RMB 1,000 million medium term note issuance at a 2.07% coupon and 10 year maturity, giving investors new information on its long term funding mix. Set against that new funding, Shenzhen International Holdings’ share price has been choppy. The stock is up 5.06% on a 1 month share price return but down 38.50% on a year to date share price return, while the 3 year total shareholder return of 30.17% contrasts with a 1 year total...
SEHK:1093
SEHK:1093Pharmaceuticals

How New Drug Trial Approvals At CSPC Pharmaceutical Group Stock Has Changed Its Investment Story

CSPC Pharmaceutical Group recently reported a cluster of R&D milestones, including multiple NMPA clinical trial approvals and a new Breakthrough Therapy Designation across neurological, oncology, ophthalmology and infectious disease programs. This run of new Parkinson’s, solid tumour, dry eye, influenza and head and neck cancer candidates points to more intensive R&D execution, a broader late stage workload and potentially higher development costs alongside a more diversified future revenue...
SEHK:12
SEHK:12Real Estate

Henderson Land Development (SEHK:12) Has Investors Asking A Bigger Question

Henderson Land Development (SEHK:12) has drawn attention after recent share performance data showed the stock flat on the day but down over the past week, month and past 3 months. Investors are reassessing what that means for value and income potential. Viewed over a longer stretch, Henderson Land Development has a 1-year total shareholder return that is down 4.24%, even as the 3-year total shareholder return sits at 55.64%. This suggests that longer term holders have seen gains while shorter...
SEHK:6990
SEHK:6990Biotechs

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Wins HER2 Approval, Is The Upside Already Priced In?

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) just cleared an important hurdle. Positive phase III data for its HER2 antibody drug trastuzumab botidotin, together with Chinese regulatory approval, now anchors a key part of the investment story. In the short term, the Sichuan Kelun-Biotech Biopharmaceutical share price has pulled back. The 1-day move is down 3.91% and the 30-day share price return is down 11.16%. However, the 90-day share price return is up 14.63% and the 3-year total...
SEHK:2096
SEHK:2096Pharmaceuticals

What Is Driving Simcere Pharmaceutical Group (SEHK:2096) Higher Today?

Simcere Pharmaceutical Group (SEHK:2096) has hit two major milestones within days. Chinese regulators approved its Culevibart Injection for RSV prevention in newborns and infants, and Roche licensed SIM0660 with material upfront, milestone and royalty economics. These twin announcements have come as Simcere Pharmaceutical Group’s share price has climbed 14.59% over the past 90 days, even though the 1-year total shareholder return is down 15.46% and the 3-year total shareholder return is up...
SEHK:2162
SEHK:2162Biotechs

Can Keymed Biosciences (SEHK:2162) Justify Its Valuation Following The Aeira Licensing Deal?

Keymed Biosciences (SEHK:2162) has moved back into focus after signing an exclusive licensing and commercialization agreement with Aeira that covers its IL-4Ra-targeted antibody Kangyueda across Southeast and Central Asia. Recent trading has been choppy for Keymed Biosciences. The share price is up 2.60% over the past day to HK$74.95, yet the 7 day and 30 day share price returns are down 4.03% and 4.09%. The 90 day and year to date share price returns of 33.13% and 40.22% point to stronger...
SEHK:1070
SEHK:1070Consumer Durables

How Investors Are Reacting To TCL Electronics Holdings (SEHK:1070) AI Home Product Launches

TCL Electronics used IFA 2026 to showcase its AI Inspired Life concept, unveiling X11L SQD Mini LED TVs, RayNeo GT Max Dolby Vision AR glasses, the NXTHOME smart home ecosystem, AI-powered appliances and new S-Class Dolby Atmos soundbars that link entertainment, appliances and energy solutions into one connected experience. The breadth of TCL Electronics' product slate, from premium Mini LED displays and AR wearables through to AI-driven air conditioning, laundry and audio, points to a push...
SEHK:992
SEHK:992Tech

Lenovo Group (SEHK:992) Climbed, But What Is Behind The Fresh Attention?

Lenovo Group (SEHK:992) has just put a spotlight on its AI and hardware roadmap at Lenovo Innovation World '26, unveiling the AeroBlade concept notebook, wider Lenovo and Motorola Qira services, fresh Yoga and Idea devices, and a new workflow partnership with Workato. For context, Lenovo Group’s share price has climbed strongly over the year, with a year to date share price return of 236.54% and a very large 5 year total shareholder return of 382.60%. However, the 30 day share price return of...
SEHK:3
SEHK:3Gas Utilities

Hong Kong and China Gas (SEHK:3) Draws Valuation Focus, Is The Premium Already Too High?

Hong Kong and China Gas (SEHK:3) recently drew investor attention after fresh performance figures showed modest revenue and net income growth, along with total returns that differ sharply between the past 3 years and the longer 5 year period. Recent trading has been mixed for Hong Kong and China Gas, with the 30-day share price return of 5.19% and 90-day gain of 5.74% contrasting with a year-to-date share price move that is roughly flat. The 3-year total shareholder return of 50.33% points to...
SEHK:3330
SEHK:3330Metals and Mining

Lingbao Gold Group (SEHK:3330), Why Is The Market Taking Another Look?

Lingbao Gold Group (SEHK:3330) has been drawing fresh attention after recent share price moves, with the stock up over the past month and past 3 months, prompting investors to reassess its valuation. Short term momentum for Lingbao Gold Group has cooled slightly, with the share price slipping 0.94% over the past day, although a 30 day share price return of 8.68% and a 90 day gain of 50.19% point to strong recent interest. Over a longer horizon, total shareholder return has been very large,...
SEHK:9863
SEHK:9863Auto

Asian Growth Companies With High Insider Ownership To Watch

As global markets navigate the complexities of geopolitical tensions and fluctuating oil prices, Asian equities have shown resilience, with growth companies continuing to capture investor interest. In this environment, stocks with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business.